Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-10-05

Clinical Trial Update: Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice

View source ↗

Summary

This post-marketing surveillance study evaluates dosing patterns, safety, and effectiveness of INLYTA (axitinib) in real-world Taiwan practice.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • INLYTA (AXITINIB)

Snippet

Sponsor: Pfizer | Conditions: Renal Cell Carcinoma | Status: COMPLETED | Results posted: 2017-10-05